Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $165 from $164 and keeps a Strong Buy rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $129 from $112 at Baird
- Mirum Pharmaceuticals price target raised to $136 from $130 at Stifel
- Mirum Pharmaceuticals price target raised to $138 from $135 at Evercore ISI
- Mirum Pharmaceuticals price target raised to $185 from $175 at H.C. Wainwright
- Mirum Pharmaceuticals reports Q1 EPS ($13.43), consensus (35c)
